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h i g h l i g h t s
• The interface area of solid tumours with normal tissue displays marked fluctuations.
• Heuristic arguments suggest that the fluctuations have a lognormal distribution.
• We utilise metabolic growth data to obtain the magnitude of the fluctuations.
• Our statistical analysis strongly supports the lognormal conjecture.
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a b s t r a c t
In a recent analysis of metabolic scaling in solid tumours we found a scaling law that
interpolates between the power laws µ ∝ V and µ ∝ V 2/3, where µ is the metabolic
rate expressed as the glucose absorption rate and V is the tumour volume. The scaling law
fits quite well both in vitro and in vivo data, however we also observedmarked fluctuations
that are associated with the specific biological properties of individual tumours. Here we
analyse these fluctuations, in an attempt to find the population-wide distribution of an
important parameter (A) which expresses the total extent of the interface between the
solid tumour and the non-cancerous environment. Heuristic considerations suggest that
the values of the A parameter follow a lognormal distribution, and, allowing for the large
uncertainties of the experimental data, our statistical analysis confirms this.
© 2017 Elsevier B.V. All rights reserved.
1. Introduction
The allometric laws of biology are power laws that describe in simple and universal terms some of the features that
are common to the vast diversity of living organisms [1–3]. Their simplicity hides the ambitious aim of encapsulating in a
single equation the huge variability and diverse dynamics that belong to living systems. Sometimes, their purely empirical
character has produced controversy, and some of these laws are not universally accepted [4–6]. Kleiber’s law is one such
scaling law: it states that the basal metabolic rate of an organism of mass M scales as M3/4 = M0.75 [7] instead of the
naive estimate M2/3 ≈ M0.67, and it has both supporters and opponents. Kleber’s law has long been mysterious and
only in recent years it has found the backing of a biological argument based on fractal structure of microcirculation [8],
which is however still controversial [9–11,11]. Nonetheless, the law has been applied also outside the domain of validity
of the supporting argument, as in the case of the metabolism of solid tumours [12]. Indeed, microcirculation in tumour
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Fig. 1. Metabolic rate data µˆN = µ/ηA1/3 vs. V/A (µm3). The figure shows a breakdown of the data originally presented in [13]. Upper panel: tumour
spheroids cultured in vitro using different cell lines. Lower panel: data from human tumours, that include breast, uterine and ovarian carcinomas,
melanomas, thyroid carcinomas, colon and lung carcinomas. All of these human tumours correspond presumably to different cell-specific metabolic rates
η. The dotted line is µˆN = V , while the dashed line is µˆN = V 2/3, which are the extreme behaviours derived from Eq. (1).
tissues is quite different from normal tissues, with an ensuing wide-ranging variability of cellular phenotypes and local
microenvironments. However, it is well-known that there is a strong correlation between tumour microenvironment and
aggressiveness, and this provides a strong motivation to study the microscopic origin of any metabolic scaling law that may
arise in this context.
We have recently proposed a metabolic scaling law for solid tumours that describes quite well both in vitro and in vivo
experimental data (see Fig. 1) [13]. Its peculiarity is that it has been obtained with the help of a computational description
of metabolism at the single-cell level which provides the link with the microscopic features of tumours [14–16]. The law is
not quite a power law, and it is given by the following expression:
µ =
(
c
vc
)
3λV
3λ+ (V/A)1/3 (1)
where µ is the metabolic rate expressed as the glucose absorption rate, V is the tumour volume, vc is the mean cell volume,
c is the cell-specific consumption rate of a single cell [13], and A is a non-dimensional parameter whose meaning will be
clarified below. The λ parameter is a characteristic length in an exponential law that describes the decay of the fraction of
live cells with increasing distance from the blood vessels (see [16] for details). The ratio η = c/vc in Eq. (1) is independent of
cell size, since c is roughly proportional to cell volume. Eq. (1) shows that the metabolic rate interpolates between the two
power-laws
µ ≈
(
c
vc
)
V (2)
at small volume and
µ ≈
(
c
vc
)
3λ
(3/4π)1/3
V 2/3 (3)
at large volume, and if we take the middle value of the exponent (0.84) we note that it is not very far from the exponent of
Kleiber’s law.
Turning to parameter A, we note that is related to the total extent of the interface between solid tumour and surrounding
environment, see Fig. 2: if x is a diameter (chosen between two recognisable features of the tumour) then the total interface
area S scales as S = Ax2 (see also Ref. [13]). The analysis of existing data – both in vitro and in vivo – points to a strong
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Fig. 2. Schematic view of the tumour–environment interface in solid tumours and in tumour spheroids. 1. Cross section of a solid tumour at low
magnification. Live tumour cells (T) wrap around blood vessels (BV) to form tumour cords. Because of the limited diffusion of nutrients, tumour cells
that are distant from blood vessels die and become necrotic (N). 2. Enlarged view of a single tumour cord. The density of live cells decreases at increasing
distance from blood vessels as dead cells mix with live cells. 3. A multicellular tumour spheroid (MTS) – an important in vitromodel of avascular tumours –
surrounded by culture medium (M) at low magnification. Live tumour cells (T) proliferate in the external layers, while dead cells form a necrotic core (N).
4. Enlarged view of the MTS section shown in 3: live cells mix with dead cells just as in real tumours. In both real tumours and MTS live cells wrap and fold
around the nutrient supply system, i.e. blood vessels and the external environment, respectively. The value of A is determined by the interface between the
bulk of the living tumour cells and the non cancerous environment, and this includes the network of blood vessels that supply the tumour with nutrients.
Therefore A is expected to be much higher in vascularised solid tumours than in avascular tumour spheroids.
dependence of the metabolic rate on A. In particular, we attribute the spread of data about the theoretical expression shown
in Fig. 1 to the fluctuations of A in populations of histologically similar tumours. Since the interface area of a tumour with
the normal tissue environment influences both its growth rate and its metastatic potential, these fluctuations are clinically
relevant.
In this paperwe argue that the probability distribution of A is lognormal, andwe show that the experimental data support
this conjecture.
2. Theory
The A parameter is directly related to the complexity of the interface between tumour and environment (see Fig. 2), and
the interface growth can be pictured as a gradual buildup of new features that appear on already existing elements, in a
way that is multiplicative rather than additive—as in a Kolmogorov process [17]. Such a process has already been assumed
in simple simulations of biological growth based on analogs of diffusion limited aggregation [18,19], and if growth can be
mapped on a Kolmogorov process this leads to a lognormal distribution [17,20,21]
p(A;m, σ ) = 1
A
√
2πσ 2
exp
[
− (ln A−m)
2σ 2
2]
(4)
where m and σ are the parameters that define the shape of the distribution. This type of growth has already been used in
an attempt to explain the complex structure of human lungs [22]. In this section we demonstrate the plausibility of the
lognormal conjecture and show how to obtain values of A from the data shown in Fig. 1.
2.1. The distribution of the A parameter
Fig. 2 contains two classes of solid tumours: solid tumours in vivo and tumour spheroids in vitro, and we consider the
lognormal arguments separately for each class.
2.1.1. The case of in vivo solid tumours
In this case the conjecture that the A parameter follows a lognormal distribution is made plausible by the following
considerations. In a solid tumour with total volume V and total interface area S, the interface corresponds to all the surface
where tumour cells exchange oxygen, nutrients and metabolites with the environment, and can be identified with the set
of blood vessels that traverse the tumour mass. This corresponds to a large area, and if we make the simplifying assumption
that the radius r of blood vessels is fixed, then it is given by S ≈ 2πrL, where L is the total length of the blood vessel network.
When the linear size of the volume increases by a factor α, we find that the volume increases by a factor α3 and the surface
area by a factor α2, however this also means that the total length of the blood vessel network also increases by the same
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factor α2. This tells us that blood vessels sprout new vessels, and the contribution of these new blood vessels to the total
network length is the difference between the quadratic growth and a simpler linear growth
α2L− αL = αL(α − 1). (5)
The same reasoning works also in the more general case where the growth of the interface area is not exactly quadratic, but
has a fractional exponent S ′ = αβS, then the contribution of new vessels to the growth of the network length is
αβL− αL = αL(αβ−1 − 1). (6)
Whatever the case, there cannot be a continuous growth, and the evolution of the tumour mass must be punctuated by
discrete sprouting events, with a random distribution of α at each step. We can also write
S = dV
dx
= d(α
3V0)
d(αx0)
= 3α2 V0
x0
= 3α2A0x20 (7)
in the case of growth over many sprouting events, where subscripted values are fixed at a given time t0, or also
S = dVn+1
dx
= d(α
3
n+1Vn)
d(αn+1xn)
= 3α2n+1
Vn
xn
= 3α2n+1Anx2n (8)
for growth between two sprouting events. Then we see from this equation that the actual value of A at any given time
fluctuates about an average, and that it is given by
A = α2A0 =
∏
k
α2k A0 (9)
where α is the combined, multiplicative result of many blood vessel sprouting events. This means that
ln A = 2
∑
k
lnαk + ln A0 (10)
so that ln A is a (large) sum of variates, and if the assumptions of the central limit theorem hold, then A has a lognormal
distribution.
2.1.2. The case of in vitro tumour spheroids
The previous considerations do not apply to avascular tumours like the tumour spheroids, however we can pinpoint
processes that contribute to a similar multiplicative structure in the determination of the actual interface area. Indeed, it has
long been known that tumour spheroids grown in identical conditions can have widely differing sizes at saturation [23,24],
and that this is closely related with the spheroid structure, in particular with the formation of the necrotic core: this fact
underscores the importance both of the random events at the single-cell level – the only difference in the development
of these spheroids – and of the structural elements. Another hint is provided by observations of the surface of tumour
spheroids, which is often rough and marked by hills and valleys; this fact has recently been exploited in a study of the
delivery of nanoparticles into tumour tissue [25]. Irregularities such as these are again the result of discrete and at least
partially random events, like cell death in the necrotic core and the mitoses in the outer cell layer of tumour spheroids, and
the previous reasoning applies again—although we expect to find a lognormal distribution with different parameters.
2.2. Finding A from metabolic data
Here we remark that we can use the metabolic scaling law to determine Awhen the other parameters are fixed
A ≈ V
(3λ)3(ηV/µ− 1)3 (11)
and we do so both for cultured tumour spheroids, where it is easier to estimate η, and for human tumours, using an average
η. For a given histological type, both η and λ are nearly fixed, and here we take the values of λ estimated in [13] for tumour
spheroids and for human tumours. Because of the difficulty of obtaining valid data, we also use the same datasets of [13],
that we selected after an extensive search of the existing literature. And indeed, while there are many data available, their
usability is limited by the following requirements:
• we utilise glucose absorption to define the metabolic rate; therefore all the data used in Eq. (1) or (11) must refer to
glucose;
• it is difficult to find combined values of the parameters for the same cell line;
• we cannot use data expressed in arbitrary units. This rules out many data like those obtained with uncalibrated
imaging techniques, those obtainedwith radioactivemarkerswithout any indication of the specific activity of labelled
compounds, and data normalised per gram of tumour tissue without any reference to the total amount of tissue used.
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Fig. 3. Pdf of the values of A in the case of the aggregated tumour spheroid data (spheroids from the 9 L, MR1 and Rat-T1 cell lines): the original data points
are shown as a ‘‘rug plot’’ (the positions marked by the vertical bars in the lower part of the plot). In addition to the glucose uptake values given in [13] we
have used η = 6.5×10−12 and λ = 93.9 µm for 9 L spheroids, η = 4.2×10−12 and λ = 123.6; µm for Rat-T1 spheroids; η = 8.9×10−12 and λ = 91.0 µm
for MR1 spheroids. The solid curve is the lognormal fit, the dashed line is the empirical smoothed kernel density, and the dotted line is a power-law with
exponent−1.3.
3. Calculation
We used the procedure of Section 2.2 to obtain the A values corresponding to the data shown in Fig. 1. Since these
data are affected by rather large uncertainties, the complete probability density function (pdf) of each measurements is
the convolution of the lognormal distribution with a normal distribution (wemake the usual assumption that measurement
uncertainties have a normal distribution):
p(A, σ0;m, σ ) =
∫ A
−∞
1
(A− x)√2πσ 2 exp
{
−[ln(A− x)−m]
2
2σ 2
}
1√
2πσ 20
exp
(
− x
2
2σ 20
)
dx (12)
where σ0 is the measurement error. Then the complete log-likelihood is
ln L(D;m, σ ) =
∑
i
ln p (A(i), σ0(i);m, σ ) (13)
where D = {A(i), σ0(i)}i=1,n is the set of all n data values and their measurement errors. The evaluation of the log-likelihood
requires the numerical evaluation of all the individual likelihoods, since expression (12) does not have a closed analytical
form. The log likelihood (13) is only approximate because the large measurement errors on A cannot be Gaussian – A is
a non-negative parameter – and moreover it depends strongly on the specific measurement errors σ0(i). Moreover, we
have only incomplete information on the measurement themselves and could not obtain good error estimates for many
datapoints. All of this leads to large numerical uncertainties and to inconclusive results when using the log-likelihood (13),
so that eventually we opted to fit the values A deduced with (11) with the lognormal pdf (4), and our results are also shown
in Figs. 3 and 4.
We tested the validity of the lognormal hypothesis by comparing it with a highly flexible phenomenological model, a
Gaussian mixture model with a variable number of components. We did this in a Bayesian framework, and we ranked the
different hypotheses using marginal likelihoods, both for cultured spheroids and for solid tumours.
In the case of cultured spheroids we considered a total of 35 alternative models, the lognormal model and 34 Gaussian
mixture models with a number of components ranging from 1 to 34. We defined only 34 mixture models because the data
set contains 34 samples, and therefore any more complex model would certainly be less plausible than the one with 34
components. Thus, we have the following likelihoods for individual data samples:
Lognormal model.
p(A|m, σ ) = logN(A;m, σ ). (14)
Model 1.
p(A|θ) =
1∑
i=1
αnN(A;mi, σi) θ = (α1,m1, σ1). (15)
. . .
Model 34.
p(A|θ) =
34∑
i=1
αnN(A;mi, σi) θ = ({αi}i=1,34, {mi}i=1,34, {σi}i=1,34) (16)
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Fig. 4. Pdf of the values of A in the case of human solid tumours: the original data points are shown as a ‘‘rug plot’’ (the positions marked by the vertical
bars in the lower part of the plot). In addition to the glucose uptake values given in [13] we have used η = 3.7× 10−12 and λ = 99.4 µm. The solid curve
is the lognormal fit, the dashed line is the empirical smoothed kernel density, and the dotted line is a power-law with exponent−1.3.
where logN(A;m, σ ) is the lognormal pdf with parameters m and σ as above, and N(A;m, σ ) is the normal pdf with
parametersm and σ .
We introducedweakly informative priors for thesemodels. For the lognormal one,m and σ were assigned uniform priors
from 0 to 200. For themixturemodels ofM components, we assignedM−1 uniform priors for αi in the interval 0 to 1, added
an extra improper prior for
∑M−1
i=1 αi < 1, define αM = 1−
∑M−1
i=1 αi, assigned allmi and σi to be independent and uniformly
distributed from 0 to 200, and finally we added an improper prior form1 ≤ m2 ≤ · · · ≤ mM .
To rank alternative hypotheses, we need to estimate marginal likelihoods for the alternative models. We estimated
these likelihoods using the Thermodynamic Integration method proposed by [26], and obtained the results shown in Fig. 5.
Together with the Bayes factor for preferring the lognormal model over any of the mixture models having the value of
4.45 × 1018, this indicates decisive evidence that the lognormal model should be preferred over any mixture of Gaussians.
Our solid tumour dataset has just asmany samples as the tumour spheroid dataset andwe repeated the samekind of analysis;
we used uniform priors from 0 to 200000 for them’s and σ ’s, since we expect a wider range of A. In this case the lognormal
hypothesis ranks only second (see Fig. 6), however we note that the solid tumour data are much more dependent on the
assumptions of metabolic consumption rate, etc., and therefore they carry with them potentially large systematic errors.
Moreover, the Gaussian mixture model is purely phenomenological and does not rely on laws of scaling in Biology. The
better performance of this mixture model can be explained by its relative simplicity while preserving good flexibility for
matching experimental data. Notice that the lognormal model fares better than the large majority of the highly flexible
Gaussian mixture models and in contrast to all of them it is biologically motivated.
4. Results and discussion
As noted above, the A parameter is related to the overall shape of the tumour. It is one of the factors that set the
timescale of tumour growth and has an importance of its own, as it determines both the total tumour volume and the size
of the interface between tumour and nutrient-supplying blood vessels. This interface also regulates the influx of drugs and
influences the overallmetastatic potential because it is the placewhere tumour cells can enter the blood stream. Theheuristic
considerations discussed above suggest that tumour spheroids and solid tumours in vivo both have lognormal distributions,
although with different parameters. The actual observations indicate that the distinction is correct, and show that the A
parameter becomes quite large in vascularised tumours in vivo because of the fractal nature of the capillary network that
feeds tumours [27]. The statistical analysis lends a support to the lognormal conjecture that is strong in the case of in vitro
tumours, but it is still inconclusive for in vivo tumours and a compelling statement requires additional data.
Interestingly, when the σ parameter is smaller than m the tail of the lognormal distribution provides a reasonable
approximation of a power-law distribution over several orders of magnitude, a fact that has prompted [20,21] to argue that
the ubiquitous power-law distributions may actually stem from underlying lognormals. If this turned out to be true also in
this case, then in a certain subrange of values the A parameter would display a sort of scale invariance over the population
of solid tumours—this is also illustrated in Figs. 3 and 4 where we plotted a power law∼ 1/A1.3 ≈ 1/A4/3 to show the kind
of scale-invariance that we would obtain with the present data analysis.
4.1. Conclusions
The A parameter sets the extent of the interface area, and for this reason it has an obvious correlation with tumour
aggressiveness and with the structure of the tumour microenvironment, and a detailed knowledge of its distribution can
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Fig. 5. Ranking of hypotheses in the case of in vitro tumour spheroids. The numbers on the x axis mean the number of mixture components, the y axis is
the value of the marginal likelihood.
Fig. 6. Ranking of hypotheses in the case of solid tumours in vivo. The numbers on the x axis mean the number of mixture components, the y axis is the
value of the marginal likelihood.
yield important statistical estimates on the overall behaviour of a population of solid tumours. This requires a protocol for
measuring A in a large number of cases, and we expect that studies of A for different histological tumour types can lead to
different parameter sets. Finally, the global statistical parameters could be used to assess the eventual prognosis with a given
dynamics of A in an individual tumour.
Data availability
The data used in this work are taken from our previous work, and they are listed in [13], which is available as an open
access article: http://www.nature.com/articles/srep01938.
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